πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9156829

Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9133127

Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions,

Jenrin Discovery, LLC Β· Granted Tue Sep 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9090573

Compounds as lysophosphatidic acid receptor antagonists

AMIRA PHARMACEUTICALS, INC. Β· Granted Tue Jul 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9089555

Complement antagonists and uses thereof

REGENESANCE B.V. Β· Granted Tue Jul 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9084773

Small molecule antagonists of bacterial quorum-sensing receptors

THE TRUSTEES OF PRINCETON UNIVERSITY Β· Granted Tue Jul 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9079913

Spiro-oxindole MDM2 antagonists

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Jul 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9012447

5-HT3 receptor antagonists

Takeda Pharmaceutical Company Limited Β· Granted Tue Apr 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9000173

Diamide compounds having muscarinic receptor antagonist and Ξ²2 adrenergic receptor agonist

Theravance Respiratory Company, LLC Β· Granted Tue Apr 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8980855

Minor groove binder (MGB)-oligonucleotide miRNA antagonists

Elitech Holding B.V. Β· Granted Tue Mar 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8969370

3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor anta

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8969292

High affinity leptins and leptin antagonists

The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center Β· Granted Tue Mar 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8952161

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. Β· Granted Tue Feb 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8952031

Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor ant

Theravance Biopharma R&D IP, LLC Β· Granted Tue Feb 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8927573

8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Jan 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8921348

Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders

Corcept Therapeutics Incorporated Β· Granted Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8921316

Stable liquid VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8916570

A3 adenosine receptor agonists and antagonists

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8912334

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Dec 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8901141

Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharma

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8895755

Intermediates for preparing dual-acting benzyl triazole antihypertensive agents having ang

Theravance Biopharma R&D IP, LLC Β· Granted Tue Nov 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8895579

Heterotricyclic AMPA receptor antagonists for treatment of epilepsy, pain, and other neuro

Northwestern University Β· Granted Tue Nov 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8889133

Methods of treating diabetes with Dll4 antagonists

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8883214

Implantable delivery vehicle for ocular delivery of muscarinic antagonists

The Regents of the University of California Β· Granted Tue Nov 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8877796

Spiro-oxindole MDM2 antagonists

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted